Product
BNZ-1
1 clinical trial
3 indications
Indication
Alopecia AreataIndication
Alopecia totalisIndication
Alopecia areataClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Intravenous BNZ-1 in Patients With Moderate to Severe Alopecia AreataStatus: Withdrawn, Estimated PCD: 2022-11-01